Valneva SE (0OB3.L)
EUR 1.82
(2.0%)
EUR 1.82
(2.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -64.51 Million EUR | 23.57% |
| 2022 | -99.39 Million EUR | -141.49% |
| 2021 | -46.86 Million EUR | -3.4% |
| 2020 | -46.11 Million EUR | -548.31% |
| 2019 | 9.71 Million EUR | -29.77% |
| 2018 | 12.84 Million EUR | 95.78% |
| 2017 | 3.64 Million EUR | 909.8% |
| 2016 | -31.47 Million EUR | 26.77% |
| 2015 | 9.76 Million EUR | 88.95% |
| 2014 | -9.18 Million EUR | 12.56% |
| 2013 | -13.35 Million EUR | -69.41% |
| 2012 | -7.68 Million EUR | -635.15% |
| 2011 | 795 Thousand EUR | 82.23% |
| 2010 | -6.07 Million EUR | -46.73% |
| 2009 | -4.7 Million EUR | -116.79% |
| 2008 | -1.82 Million EUR | 39.63% |
| 2007 | -3.01 Million EUR | -662.01% |
| 2006 | 605 Thousand EUR | -42.26% |
| 2005 | 998 Thousand EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -22.35 Million EUR | -28.46% |
| 2024 Q2 | -21.79 Million EUR | 9.81% |
| 2023 Q3 | -22.06 Million EUR | -22.13% |
| 2023 Q1 | -16.32 Million EUR | 70.93% |
| 2023 Q4 | -24.44 Million EUR | -10.78% |
| 2023 Q2 | -18.06 Million EUR | -10.7% |
| 2023 FY | - EUR | 23.57% |
| 2022 Q2 | -142.61 Million EUR | -674.7% |
| 2022 FY | - EUR | -141.49% |
| 2022 Q4 | -56.14 Million EUR | -160.18% |
| 2022 Q3 | 93.29 Million EUR | 165.42% |
| 2022 Q1 | -18.4 Million EUR | -110.44% |
| 2021 Q2 | -53.83 Million EUR | -129.45% |
| 2021 Q1 | -23.46 Million EUR | -7596.17% |
| 2021 FY | - EUR | -3.4% |
| 2021 Q3 | -160.2 Million EUR | -197.58% |
| 2021 Q4 | 176.33 Million EUR | 210.07% |
| 2020 Q3 | -26.27 Million EUR | -23.82% |
| 2020 FY | - EUR | -548.31% |
| 2020 Q2 | -21.22 Million EUR | -976.9% |
| 2020 Q1 | 2.42 Million EUR | -36.67% |
| 2020 Q4 | 313 Thousand EUR | 101.19% |
| 2019 Q2 | -5.65 Million EUR | -159.84% |
| 2019 FY | - EUR | -29.77% |
| 2019 Q4 | 3.82 Million EUR | 38.64% |
| 2019 Q3 | 2.75 Million EUR | 148.76% |
| 2019 Q1 | 9.44 Million EUR | 17.15% |
| 2018 Q2 | 1.3 Million EUR | -73.41% |
| 2018 Q1 | 4.9 Million EUR | 196.0% |
| 2018 FY | - EUR | 95.78% |
| 2018 Q4 | 8.06 Million EUR | 1983.2% |
| 2018 Q3 | 387 Thousand EUR | -70.3% |
| 2017 Q2 | 4.21 Million EUR | 24.94% |
| 2017 Q4 | -5.1 Million EUR | -235.53% |
| 2017 Q3 | 3.76 Million EUR | -10.61% |
| 2017 FY | - EUR | 909.8% |
| 2017 Q1 | 3.37 Million EUR | 869.86% |
| 2016 Q4 | -438 Thousand EUR | 63.44% |
| 2016 FY | - EUR | 26.77% |
| 2016 Q3 | -1.19 Million EUR | -131.8% |
| 2016 Q2 | 3.76 Million EUR | 9087.8% |
| 2016 Q1 | 41 Thousand EUR | -99.49% |
| 2015 Q2 | -5.28 Million EUR | -404.58% |
| 2015 Q1 | -1.04 Million EUR | 77.6% |
| 2015 FY | - EUR | 88.95% |
| 2015 Q4 | 8.02 Million EUR | 3648.13% |
| 2015 Q3 | 214 Thousand EUR | 104.05% |
| 2014 Q3 | 1.14 Million EUR | 255.98% |
| 2014 FY | - EUR | 12.56% |
| 2014 Q1 | -3 Million EUR | -42.25% |
| 2014 Q2 | -736 Thousand EUR | 75.49% |
| 2014 Q4 | -4.67 Million EUR | -507.14% |
| 2013 Q3 | -6.16 Million EUR | -87.64% |
| 2013 Q4 | -2.11 Million EUR | 65.75% |
| 2013 FY | - EUR | -69.41% |
| 2013 Q1 | -1.51 Million EUR | -5.35% |
| 2013 Q2 | -3.28 Million EUR | -116.55% |
| 2012 Q3 | -1.38 Million EUR | 0.0% |
| 2012 Q4 | -1.44 Million EUR | -4.2% |
| 2012 FY | - EUR | -635.15% |
| 2011 FY | - EUR | 82.23% |
| 2010 FY | - EUR | -46.73% |
| 2009 FY | - EUR | -116.79% |
| 2008 FY | - EUR | 39.63% |
| 2007 FY | - EUR | -662.01% |
| 2006 FY | - EUR | -42.26% |
| 2005 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Boiron SA | 80.67 Million EUR | 179.968% |
| Laboratorios Farmaceuticos Rovi, S.A. | 238.01 Million EUR | 127.106% |
| Vetoquinol SA | 104.58 Million EUR | 161.691% |
| AB Science S.A. | -9.28 Million EUR | -595.151% |
| Nanobiotix S.A. | -34.01 Million EUR | -89.65% |
| PHAXIAM Therapeutics S.A. | -22.93 Million EUR | -181.365% |
| Vivoryon Therapeutics N.V. | -28.35 Million EUR | -127.549% |
| BioSenic S.A. | -6.79 Million EUR | -849.338% |
| ABIVAX Société Anonyme | -133.2 Million EUR | 51.566% |
| Formycon AG | 81.05 Million EUR | 179.599% |